BioNTech continues pipeline buildout with WuXi antibody deal

2024-01-11

疫苗引进/卖出并购临床2期

BioNTech’s burgeoning cancer portfolio could gain two more antibodies, thanks to a discovery deal the company signed Thursday with WuXi Biologics. Flush with cash from its successful COVID-19 vaccine COVID-19 vaccine, BioNTech has been on a spending spree since late 2022 to bulk out its pipeline as vaccine revenues decline.

WuXi will receive $20 million upfront to discover two monoclonal antibodies (mAbs) against undisclosed targets for BioNTech. The Chinese CRDMO is also eligible for undisclosed research, development, regulatory and commercial milestones, plus tiered royalties.

The partnership is at least the sixth recent discovery or licensing-focused deal from BioNTech, spanning small molecule, mAb, bispecific, and antibody drug conjugate (ADC) modalities intended to treat cancer. The company also completed an acquisition of InstaDeep in July 2023 for about €500 million in cash, gaining its artificial intelligence-driven drug discovery and development platform.

The most recent deal came in November when BioNTech agreed to spend up to $1 billion to develop Biotheus’ bispecific antibody candidate PM8002. The experimental drug, which is currently being investigated in Phase II studies in patients with advanced solid tumours, consists of humanised anti-PD-L1 single heavy-chain variable domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations.

At the same time it announced the Biotheus collaboration, BioNTech had said it expects 2023 revenue from its COVID-19 vaccine Comirnaty of around €4 billion ($4.3 billion), down from an earlier forecast of about €5 billion.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构